Sanghoon Park
founder & CEO of Illimis Therapeutics
Contact
Companies
Company
Roles
Illimis Therapeutics
Illimis Therapeutics specializes in developing novel biologics based on its proprietary chimeric fusion protein platform. The platform aims to address neurodegenerative diseases such as Alzheimer's by utilizing TAM receptor-mediated phagocytosis, which reduces neuroinflammation
CEO